AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31651951 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet monotherapy
Number of subjects: 15092
Study 31651951 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 15092
Study 31651951 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC use in patients aged 65-74, 75-84, and ≥85 years with high bleeding risk (HAS-BLED ≥3)
Number of subjects: 15092
Study 31651951 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet only in patients aged 65-74, 75-84, and ≥85 years with high bleeding risk (HAS-BLED ≥3)
Number of subjects: 15092
Study 31651951 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC use in patients ≥85 years by region
Number of subjects: 15092
Study 31651956 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning classifiers (specifically XGBoost) for imputation of self-harm events
Number of subjects: 10120030
Study 31651956 — intervention group
Group type: COMPARATOR
Intervention: Coded self-harm events
Number of subjects: 10120030
Study 31651956 — intervention group
Group type: EXPERIMENTAL
Intervention: Imputed self-harm events
Number of subjects: 10120030
Study 31651956 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning features used for classification
Number of subjects: 10120030
Study 31651956 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-harm undercoding in males vs females
Number of subjects: 10120030
Study 31651956 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-harm undercoding in seniors
Number of subjects: 10120030
Study 31652009 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation starting at 65 mg daily, titrated based on fasting serum iron concentration.
Number of subjects: 6
Study 31652009 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation
Number of subjects: 6
Study 31652392 — intervention group
Group type: EXPERIMENTAL
Intervention: SOF/VEL (sofosbuvir/velpatasvir) pretransplant and on posttransplant Day 1 (Group 1)
Number of subjects: 50
Study 31652392 — intervention group
Group type: EXPERIMENTAL
Intervention: SOF/VEL (sofosbuvir/velpatasvir) on Days 2 and 3 posttransplant (Group 2A and Group 2B)
Number of subjects: 50
Study 31652392 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day SOF/VEL strategy
Number of subjects: 50
Study 31652392 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant DAA therapy for viremic patients
Number of subjects: 50
Study 31652392 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient and allograft survivals
Number of subjects: 50
Study 31652401 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal study examining leukocyte telomere length (LTL) in children and their parents
Number of subjects: 0
Study 31652765 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Physical Exercise
Number of subjects: 52
Study 31652765 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 31652997 — intervention group
Group type: EXPERIMENTAL
Intervention: RC28-E (5 mg/kg, 15 mg/kg, and 50 mg/kg, ip. Tiw × 9)
Number of subjects: 0
Study 31652997 — intervention group
Group type: COMPARATOR
Intervention: Mono-target antagonist treatment (VEGF or FGF blocking)
Number of subjects: 0
Study 31652997 — intervention group
Group type: EXPERIMENTAL
Intervention: RC28-E
Number of subjects: 0
Study 31653207 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) measurements taken at ED presentation
Number of subjects: 1084
Study 31653207 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) measurements taken at ED presentation
Number of subjects: 1084
Study 31653352 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial shunt device (IASD) implantation
Number of subjects: 64
Study 31653796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided L5 dorsal ramus block using a pivot technique
Number of subjects: 100
Study 31654156 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 100
Study 31654272 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg/day (initial alemtuzumab treatment; IAT) for 5 days initially, then 3 days 12 months later
Number of subjects: 43
Study 31654272 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (pooled IAT/DAT)
Number of subjects: 43
Study 31654272 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (IAT only)
Number of subjects: 43
Study 31654272 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous interferon beta-1a (SC IFNB-1a) 3×/week (control)
Number of subjects: 43
Study 31654285 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg PO daily and panobinostat 10 mg PO 3 times weekly (weeks 1 and 2) given in 21-day cycles
Number of subjects: 21
Study 31654285 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus/panobinostat therapy
Number of subjects: 21
Study 31654285 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-605 levels
Number of subjects: 21
Study 31654541 — intervention group
Group type: EXPERIMENTAL
Intervention: High angiogenic tumor (HAT)
Number of subjects: 184
Study 31654541 — intervention group
Group type: EXPERIMENTAL
Intervention: Low angiogenic tumor (LAT)
Number of subjects: 184
Study 31654541 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltrated peripheral edema (IPE)
Number of subjects: 184
Study 31654541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasogenic peripheral edema (VPE)
Number of subjects: 184
Study 31655045 — intervention group
Group type: EXPERIMENTAL
Intervention: GSEED-RE model
Number of subjects: 1034
Study 31655045 — intervention group
Group type: EXPERIMENTAL
Intervention: ACER model
Number of subjects: 1034
Study 31655045 — intervention group
Group type: EXPERIMENTAL
Intervention: GSEED-RE2 model
Number of subjects: 1034
Study 31655045 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prediction models (GSEED-RE and ACER)
Number of subjects: 1034
Study 31655045 — intervention group
Group type: COMPARATOR
Intervention: Factors associated with delayed bleeding
Number of subjects: 1034
Study 31655222 — intervention group
Group type: EXPERIMENTAL
Intervention: ACVR1 (R206H) mutation in individuals with FOP
Number of subjects: 113
Study 31655936 — intervention group
Group type: EXPERIMENTAL
Intervention: telotristat ethyl treatment
Number of subjects: 135
Study 31656217 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced ERN in children with high BI
Number of subjects: 291
Study 31656217 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunted ERN in children with high childhood irritability
Number of subjects: 291
Study 31448107 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Exercise after Total Hip Arthroplasty
Number of subjects: 0
Study 31448107 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31656630 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting to the affected area of skin
Number of subjects: 1
Study 31656987 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestive lymphatic therapy (DLT)
Number of subjects: 8
Study 31656987 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-borne costs
Number of subjects: 8
Study 31656987 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect costs borne by patients
Number of subjects: 8
Study 31656987 — intervention group
Group type: EXPERIMENTAL
Intervention: Society-borne costs
Number of subjects: 8
Study 31657082 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) treatment for 7 days in GC-resistant patients (n=7)
Number of subjects: 49
Study 31657082 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) treatment
Number of subjects: 49
Study 31657503 — intervention group
Group type: EXPERIMENTAL
Intervention: Vineland-3
Number of subjects: 106
Study 31657648 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast Growth Factor Receptor Inhibitors
Number of subjects: 0
Study 31657964 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% increase in step rate using an audible metronome during a single session of gait retraining
Number of subjects: 12
Study 31657964 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 31658128 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Sleeve Gastroplasty (ESG)
Number of subjects: 109
Study 31658475 — intervention group
Group type: COMPARATOR
Intervention: Unguided biopsy
Number of subjects: 40
Study 31658475 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopically guided biopsy
Number of subjects: 40
Study 31658475 — intervention group
Group type: EXPERIMENTAL
Intervention: All cases (combined results)
Number of subjects: 40
Study 31658475 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision surgery
Number of subjects: 40
Study 31659543 — intervention group
Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTA)
Number of subjects: 150
Study 31659631 — intervention group
Group type: EXPERIMENTAL
Intervention: Authors' predictive model using CK19 mRNA and CEUS score
Number of subjects: 235
Study 31659631 — intervention group
Group type: COMPARATOR
Intervention: MSKCC nomogram
Number of subjects: 235
Study 31659739 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy (AT)
Number of subjects: 136
Study 31659847 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI)
Number of subjects: 11
Study 31659915 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 0
Study 31659915 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proANP
Number of subjects: 0
Study 31660391 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (maintained serum 25(OH)D >30 ng/mL)
Number of subjects: 260
Study 31660391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 31660640 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib de-escalation (from 10 mg b.d. to 5 mg b.d.)
Number of subjects: 123
Study 31660640 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib escalation (from 5 mg b.d. to 10 mg b.d.)
Number of subjects: 123
Study 31660903 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by total mesorectal excision
Number of subjects: 84
Study 31660992 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative surgery for rectal adenocarcinoma
Number of subjects: 188
Study 31661079 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vital sign monitoring with alerts sent to nursing staff
Number of subjects: 2049
Study 31661079 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth technology for patient monitoring
Number of subjects: 2049
Study 31661339 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAM (Cladribine + AraC + Mitoxantrone)
Number of subjects: 253
Study 31661339 — intervention group
Group type: COMPARATOR
Intervention: DAC (Daunorubicin + AraC + Cladribine)
Number of subjects: 253
Study 31661339 — intervention group
Group type: EXPERIMENTAL
Intervention: DAC reinduction
Number of subjects: 253
Study 31661339 — intervention group
Group type: COMPARATOR
Intervention: Not receiving CLAM
Number of subjects: 253
Study 31661339 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 253
Study 31661530 — intervention group
Group type: EXPERIMENTAL
Intervention: Skhokho intervention, details on dosage and duration not available
Number of subjects: 0
Study 31661530 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 31661690 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS_C
Number of subjects: 30
Study 31661690 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS_B
Number of subjects: 30
Study 31662377 — intervention group
Group type: EXPERIMENTAL
Intervention: MD Anderson Symptom Inventory-Lung Cancer Module (MDASI-LC) for symptom data collection preoperatively, daily postoperatively during in-hospital stay, and weekly after discharge until 4 weeks or start of postoperative oncological therapy.
Number of subjects: 300
Study 31662377 — intervention group
Group type: EXPERIMENTAL
Intervention: MD Anderson Symptom Inventory-Lung Cancer Module (MDASI-LC) interference-measured functional status as an anchor for alert thresholds.
Number of subjects: 300
Study 31662404 — intervention group
Group type: EXPERIMENTAL
Intervention: T-MACS decision aid algorithm with point-of-care troponin assays
Number of subjects: 0
Study 31662412 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/d IV; 5 days at baseline, 3 days 12 months later)
Number of subjects: 0
Study 31662412 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (as-needed or other disease-modifying therapy in a 4-year extension)
Number of subjects: 0
Study 31662765 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin scaffold with hMSSM-derived cells
Number of subjects: 0
Study 31662765 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen scaffold with hMSSM-derived cells
Number of subjects: 0
Study 31662765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite/tricalcium phosphate (HA) scaffold with hMSSM-derived cells
Number of subjects: 0
Study 31662765 — intervention group
Group type: COMPARATOR
Intervention: Control (fibrin/thrombin scaffold with hMSSM-derived cells)
Number of subjects: 0
Study 31662801 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended release (TA-ER) 32 mg into each knee (total 64 mg)
Number of subjects: 0
Study 31662801 — intervention group
Group type: COMPARATOR
Intervention: Traditional triamcinolone acetonide crystalline suspension (TAcs) 40 mg into each knee (total 80 mg)
Number of subjects: 0
Study 31662874 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Ezetimibe
Number of subjects: 1136
Study 31662874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136
Study 31662893 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepithelial AXL
Number of subjects: 20
Study 31662893 — intervention group
Group type: COMPARATOR
Intervention: Epithelium-off AXL
Number of subjects: 20
Study 31663247 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with POH (cases)
Number of subjects: 303
Study 31663247 — intervention group
Group type: COMPARATOR
Intervention: Patients without POH (controls)
Number of subjects: 303
Study 31663410 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0
Study 31663410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 0
Study 31663410 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31663465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg + methotrexate
Number of subjects: 0
Study 31663465 — intervention group
Group type: COMPARATOR
Intervention: Abatacept + methotrexate
Number of subjects: 0
Study 31663465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab + methotrexate
Number of subjects: 0
Study 31663906 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless motility capsules (WMC)
Number of subjects: 150
Study 31663906 — intervention group
Group type: COMPARATOR
Intervention: Gastric emptying scintigraphy (GES)
Number of subjects: 150
Study 31663906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests (WMC and GES)
Number of subjects: 150
Study 31664603 — intervention group
Group type: EXPERIMENTAL
Intervention: Young patients (18 to 54 years)
Number of subjects: 618
Study 31664603 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged patients (55 to 67 years)
Number of subjects: 618
Study 31664603 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients (67 years and older)
Number of subjects: 618
Study 31664603 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (biomarker of coagulation)
Number of subjects: 618
Study 31664941 — intervention group
Group type: EXPERIMENTAL
Intervention: High prenatal maternal stress (scores >5)
Number of subjects: 353
Study 31664941 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate prenatal maternal stress (scores 3-5)
Number of subjects: 353
Study 31664962 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression ≥50%
Number of subjects: 154
Study 31664962 — intervention group
Group type: COMPARATOR
Intervention: PD-L1 expression <50%
Number of subjects: 154
Study 31664962 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF mutation positive
Number of subjects: 154
Study 31664962 — intervention group
Group type: COMPARATOR
Intervention: BRAF mutation negative
Number of subjects: 154
Study 31665006 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stroke activity limitations evaluated by the modified Rankin score
Number of subjects: 100
Study 31665006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive disorders assessed by standardized and validated scales
Number of subjects: 100
Study 31665006 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxio-depressive disorders assessed by standardized and validated scales
Number of subjects: 100
Study 31665006 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue assessed by standardized and validated scales
Number of subjects: 100
Study 31665006 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction of participation assessed by standardized and validated scales
Number of subjects: 100
Study 31665021 — intervention group
Group type: EXPERIMENTAL
Intervention: I-FFQ
Number of subjects: 137
Study 31665061 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compressions during CPR
Number of subjects: 30
Study 31665141 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-stable toxin-based vaccine candidates, dosage and duration not specified
Number of subjects: 0
Study 31665349 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded IV glucose infusion
Number of subjects: 32
Study 31665349 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine administration
Number of subjects: 32
Study 31665349 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexposed)
Number of subjects: 32
Study 31665380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-18 (Cer-18)
Number of subjects: 2337
Study 31665380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-20 (Cer-20)
Number of subjects: 2337
Study 31665380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-22 (Cer-22)
Number of subjects: 2337
Study 31665380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-24 (Cer-24)
Number of subjects: 2337
Study 31665380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-16 (Cer-16)
Number of subjects: 2337
Study 31665380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingomyelins (SMs)
Number of subjects: 2337
Study 31665380 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosyl-ceramides
Number of subjects: 2337
Study 31665380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactosyl-ceramide
Number of subjects: 2337
Study 31665480 — intervention group
Group type: COMPARATOR
Intervention: hGIP1-42 infusion during fasting glycemia
Number of subjects: 22
Study 31665480 — intervention group
Group type: COMPARATOR
Intervention: hGIP1-42 infusion during hyperglycemic clamping
Number of subjects: 22
Study 31665480 — intervention group
Group type: COMPARATOR
Intervention: hGIP1-42 infusion during insulin-induced hypoglycemia
Number of subjects: 22
Study 31665480 — intervention group
Group type: EXPERIMENTAL
Intervention: pGIP1-42 infusion in isolated porcine pancreata
Number of subjects: 22
Study 31665959 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP 30 to <60 mm Hg
Number of subjects: 2897
Study 31665959 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 90 to <120 mm Hg
Number of subjects: 2897
Study 31665959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SBP (<120 mm Hg)
Number of subjects: 2897
Study 31665959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower DBP (<60 mm Hg)
Number of subjects: 2897
Study 31666040 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal motivation to lose weight
Number of subjects: 3008
Study 31666040 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to talk to a diabetes educator about weight
Number of subjects: 3008
Study 31666040 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss attempts recognized by a healthcare provider
Number of subjects: 3008
Study 31666040 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of 'obesity' or 'overweight'
Number of subjects: 3008
Study 31666061 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine infection-prevention methods in the ED
Number of subjects: 446
Study 31666061 — intervention group
Group type: COMPARATOR
Intervention: Routine infection-prevention methods in the GW
Number of subjects: 446
Study 31666061 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk individuals in the ED
Number of subjects: 446
Study 31666061 — intervention group
Group type: COMPARATOR
Intervention: High-risk individuals in the GW
Number of subjects: 446
Study 31666061 — intervention group
Group type: COMPARATOR
Intervention: Attack rate of MERS in the GW
Number of subjects: 446
Study 31666061 — intervention group
Group type: EXPERIMENTAL
Intervention: Attack rate of MERS in the ED
Number of subjects: 446
Study 31666061 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmission in intermediate- and low-risk groups in the ED
Number of subjects: 446
Study 31666061 — intervention group
Group type: COMPARATOR
Intervention: Transmission in low-risk group in the GW
Number of subjects: 446
Study 31666082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous EEG
Number of subjects: 4
Study 31666082 — intervention group
Group type: COMPARATOR
Intervention: Long-term video scalp EEG (LTV EEG)
Number of subjects: 4
Study 31666237 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 750 mg immediately then 250 mg every 8 hours for 7 days
Number of subjects: 399
Study 31666237 — intervention group
Group type: COMPARATOR
Intervention: low-dose colchicine 500 mcg three times per day for 4 days
Number of subjects: 399
Study 31666276 — intervention group
Group type: COMPARATOR
Intervention: Screening for HLH in 16 ICUs, diagnosis based on HLH-2004 criteria and expert review.
Number of subjects: 100
Study 31666276 — intervention group
Group type: COMPARATOR
Intervention: Exploration of a panel of potential biomarker candidates.
Number of subjects: 100
Study 31667609 — intervention group
Group type: EXPERIMENTAL
Intervention: Second trimester serum lipids
Number of subjects: 748
Study 31667609 — intervention group
Group type: EXPERIMENTAL
Intervention: Third trimester serum lipids
Number of subjects: 748